Trial reportObesity (Silver Spring, Md.)2020
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Trial report in Obesity (Silver Spring, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives.Biomedicines · 2025Review
- Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies.Diabetology & metabolic syndrome · 2025Review
- Gliflozins in hypertension: basic mechanisms and clinical insights.American journal of physiology. Renal physiology · 2025Review
- Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity.Cancers · 2024Review
- A review of the evidence on cardiovascular outcomes from obesity treatment.Obesity pillars · 2023Review
- 360-Degree Perspectives on Obesity.Medicina (Kaunas, Lithuania) · 2023Review
- Pharmacological Support for the Treatment of Obesity-Present and Future.Healthcare (Basel, Switzerland) · 2023Review
- Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.Frontiers in endocrinology · 2023Review
- Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass.Obesity surgery · 2022Article
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.International journal of molecular sciences · 2022Review
- Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?Current obesity reports · 2021Review
- Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice.Therapeutic advances in endocrinology and metabolism · 2021Review
- Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.World journal of gastroenterology · 2020Review
- Exploring Bariatric Surgery's Impact on Weight Loss and Diabetes: Sodium and Glucose Receptor Modulation.JSLS : Journal of the Society of Laparoendoscopic SurgeonsReview
- WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES: A SYSTEMATIC REVIEW.Acta endocrinologica (Bucharest, Romania : 2005)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe aim of this study was to explore the dose response of licogliflozin, a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), by evaluating change in body weight in adults with overweight or obesity.
methodsThis dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2.5-150 mg) versus placebo (primary end point). A further 24-week analysis evaluated the efficacy and safety of two once-daily licogliflozin doses in maintaining initial weight reduction.
resultsLicogliflozin once daily or twice daily produced a significant dose-response signal for weight loss versus placebo (P < 0.0001). However, mean adjusted percent changes in body weight after 24 weeks were modest, ranging from -0.45% to -3.83% (in the 50 mg twice daily group [95% CI: -5.26% to -2.48%]; n = 75). Responder analysis of ≥ 5% weight loss at week 24 revealed significant differences versus placebo, which were most pronounced with highest doses of 50 mg twice daily (45.3%) and 150 mg once daily (42.9%) (both P < 0.01). While weight loss was greater at higher doses, gastrointestinal adverse events were also more frequent. The 50-mg once-daily dose had perhaps the best balance between efficacy and tolerability.
conclusionsLicogliflozin produced significant reductions in body weight versus placebo. However, the magnitude of weight reduction was modest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.